| scholarly article | Q13442814 |
| P2093 | author name string | Harold I Feldman | |
| Simcha Pollack | |||
| Marshall M Joffe | |||
| Steven Fishbane | |||
| P2860 | cites work | Studies of the pathogenesis of anemia of inflammation: mechanism of impaired erythropoiesis | Q71092245 |
| The evaluation of iron status in hemodialysis patients | Q71959554 | ||
| KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease | Q83296275 | ||
| II. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults | Q83296279 | ||
| K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification | Q29547560 | ||
| Prevalence of chronic kidney disease in the United States | Q29614191 | ||
| Prediction of creatinine clearance from serum creatinine | Q29615603 | ||
| Iron management in end-stage renal disease | Q41354609 | ||
| Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. | Q43862992 | ||
| Iron status and hemoglobin level in chronic renal insufficiency | Q44192011 | ||
| Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study | Q44747060 | ||
| Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients | Q46217820 | ||
| Calibration of serum creatinine in the National Health and Nutrition Examination Surveys (NHANES) 1988-1994, 1999-2004. | Q46883348 | ||
| Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron. | Q50733265 | ||
| Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. | Q51052485 | ||
| Predictive value of a positive fecal occult blood test increases as the severity of CKD worsens. | Q51932886 | ||
| Predicting glomerular function from adjusted serum creatinine | Q55037699 | ||
| Iron status in patients receiving erythropoietin for dialysis-associated anemia | Q69590794 | ||
| P433 | issue | 1 | |
| P921 | main subject | chronic renal insufficiency | Q736715 |
| P304 | page(s) | 57-61 | |
| P577 | publication date | 2008-11-05 | |
| P1433 | published in | Clinical Journal of the American Society of Nephrology | Q15757929 |
| P1476 | title | Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988-2004. | |
| P478 | volume | 4 |
| Q35105827 | A 3-marker index improves the identification of iron disorders in CKD anaemia. |
| Q37682229 | A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD. |
| Q36108862 | A randomized trial of intravenous and oral iron in chronic kidney disease |
| Q43633394 | Anaemia management and mortality risk in newly visiting patients with chronic kidney disease in Japan: The CKD-ROUTE study |
| Q44927431 | Anaemia management in non-dialysis chronic kidney disease (CKD) patients: a multicentre prospective study in renal clinics. |
| Q87502351 | Anaemia: FIND-CKD: intravenous iron in predialysis CKD |
| Q99241001 | Anemia and iron deficiency among chronic kidney disease Stages 3-5ND patients in the Chronic Kidney Disease Outcomes and Practice Patterns Study: often unmeasured, variably treated |
| Q37235968 | Anemia, diabetes, and chronic kidney disease |
| Q93054919 | Association Between Iron Status and Risk of Chronic Kidney Disease in Chinese Adults |
| Q36381297 | Association between common iron store markers and hemoglobin in children with chronic kidney disease |
| Q36111521 | Beyond the cardiorenal anaemia syndrome: recognizing the role of iron deficiency |
| Q33684085 | Can the response to iron therapy be predicted in anemic nondialysis patients with chronic kidney disease? |
| Q56761591 | Clinical experience with the use of ferric citrate as a phosphate binder in pediatric dialysis patients |
| Q38939078 | Controversial issues in CKD clinical practice: position statement of the CKD-treatment working group of the Italian Society of Nephrology. |
| Q34989324 | Correction of iron deficiency in the cardiorenal syndrome |
| Q35067500 | Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease |
| Q39192941 | Diagnosing and preventing iron overload |
| Q38566828 | Diagnosis of iron-deficient states |
| Q90470184 | Effect of renal function and dialysis modality on daprodustat and predominant metabolite exposure |
| Q46279772 | Effects of Ferric Citrate in Patients with Nondialysis-Dependent CKD and Iron Deficiency Anemia |
| Q95420869 | Erythropoietic response to oral iron in patients with nondialysis-dependent chronic kidney disease in the FIND-CKD trial |
| Q64271549 | Ethnic prevalence of anemia and predictors of anemia among chronic kidney disease patients at a tertiary hospital in Johannesburg, South Africa |
| Q36086930 | Ferumoxytol versus iron sucrose treatment: a post-hoc analysis of randomized controlled trials in patients with varying renal function and iron deficiency anemia |
| Q37661506 | Ferumoxytol: a new intravenous iron preparation for the treatment of iron deficiency anemia in patients with chronic kidney disease |
| Q38114158 | How can erythropoeitin-stimulating agent use be reduced in chronic dialysis patients?: The use of iron supplementation to reduce ESA dosing in hemodialysis |
| Q58700150 | Impact of Inflammation on Ferritin, Hepcidin and the Management of Iron Deficiency Anemia in Chronic Kidney Disease |
| Q36863458 | Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production |
| Q52685153 | Inhibition of fibroblast growth factor 23 (FGF23) signaling rescues renal anemia. |
| Q37807903 | Intravenous iron in heart failure: beyond targeting anemia |
| Q47102798 | Intravenous iron therapy in patients with chronic kidney disease: recent evidence and future directions |
| Q38023804 | Intravenous versus oral iron for treatment of iron deficiency in non-hemodialysis-dependent patients with chronic kidney disease |
| Q98178909 | Iron Administration, Infection, and Anemia Management in CKD: Untangling the Effects of Intravenous Iron Therapy on Immunity and Infection Risk |
| Q89636084 | Iron Deficiency in Chronic Kidney Disease: Updates on Pathophysiology, Diagnosis, and Treatment |
| Q36975638 | Iron Status of Cats with Chronic Kidney Disease |
| Q37069943 | Iron Therapy Challenges for the Treatment of Nondialysis CKD Patients |
| Q47550398 | Iron deficiency across chronic kidney disease stages: Is there a reverse gender pattern? |
| Q38575172 | Iron deficiency anaemia |
| Q48011055 | Iron deficiency beyond erythropoiesis: should we be concerned? |
| Q37895175 | Iron deficiency in children with early chronic kidney disease |
| Q55089372 | Limitations of Serum Ferritin in Diagnosing Iron Deficiency in Inflammatory Conditions. |
| Q92774629 | Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies |
| Q34085240 | Parenteral iron formulations differentially affect MCP-1, HO-1, and NGAL gene expression and renal responses to injury |
| Q42666051 | Plasma pharmacokinetics of two consecutive doses of ferumoxytol in healthy subjects |
| Q92648693 | Plummer-Vinson syndrome: improving outcomes with a multidisciplinary approach |
| Q35083495 | Prevalence of anemia in chronic kidney disease in the United States |
| Q36263980 | Relative Incidence of Acute Adverse Events with Ferumoxytol Compared to Other Intravenous Iron Compounds: A Matched Cohort Study |
| Q53096541 | Responsiveness to erythropoiesis-stimulating agents in chronic kidney disease: does geography matter? |
| Q46219047 | Safety and efficacy of ferric citrate in patients with nondialysis-dependent chronic kidney disease |
| Q40279708 | Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent CKD: an analysis of the 1-year FIND-CKD trial |
| Q40123974 | Serum Ferritin Variations and Mortality in Incident Hemodialysis Patients |
| Q47102803 | Special issue: iron therapy in patients with chronic kidney disease. |
| Q28648176 | Switching patients with non-dialysis chronic kidney disease from oral iron to intravenous ferric carboxymaltose: effects on erythropoiesis-stimulating agent requirements, costs, hemoglobin and iron status |
| Q37570176 | The Prevalence and Management of Anemia in Chronic Kidney Disease Patients: Result from the KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD). |
| Q33412890 | The importance of iron in long-term survival of maintenance hemodialysis patients treated with epoetin-alfa and intravenous iron: analysis of 9.5 years of prospectively collected data |
| Q34000965 | The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: a multi-centre, open-label, clinical study |
| Q57040818 | Utility of reticulocyte haemoglobin content and percentage hypochromic red cells as markers of iron deficiency anaemia among black CKD patients in South Africa |
Search more.